HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare corporate growing and commercializing precision diagnostics and radiopharmaceuticals for central frightened device (CNS) cancers, nowadays introduced that it has gained notification from The Nasdaq Inventory Marketplace LLC (“Nasdaq”) confirming the Corporate has regained compliance with the minimal bid value requirement set forth in Nasdaq Record Rule 5550(a)(2).
Nasdaq decided that, for the ten consecutive industry days from April 6, 2026 to April 17, 2026, the ultimate bid value of the Corporate’s not unusual inventory was once at or above $1.00 in line with percentage. Accordingly, Nasdaq has prompt that the topic is now closed.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical corporate growing centered radiotherapeutics for difficult-to-treat cancers of the central frightened device with the prospective to reinforce scientific results. Combining image-guided native beta radiation and centered drug supply approaches, the Corporate is advancing a pipeline of product applicants with lead techniques in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Corporate has constructed a provide chain via strategic partnerships that allow the advance, production and long term possible commercialization of its merchandise.
